Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

20.36USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$20.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
930,161
52-wk High
$32.49
52-wk Low
$18.50

Select another date:

Tue, May 22 2018

BRIEF-Exelixis Appoints Andrew Peters To Newly Created Position Of Vice President, Strategy

* EXELIXIS APPOINTS ANDREW R. PETERS TO NEWLY CREATED POSITION OF VICE PRESIDENT, STRATEGY Source text for Eikon: Further company coverage:

BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib

* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER

BRIEF-Exelixis Inc Q1 Earnings Per Share $0.37

* EXELIXIS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer

* EXELIXIS AND INVENRA ENTER INTO COLLABORATION TO DISCOVER AND DEVELOP NOVEL BIOLOGICS TO TREAT CANCER

BRIEF-Exelixis Says CEO Michael Morrissey's FY 2017 Total Compensation Was $9.4 Mln VS $6.3 Mln

* EXELIXIS INC SAYS CEO MICHAEL MORRISSEY'S FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $6.3 MLN IN 2016 - SEC FILING Source text: (https://bit.ly/2Hi8UXj) Further company coverage:

BRIEF-Exelixis Says Board Increased Size Of Board To 12 Members

* EXELIXIS SAYS BOARD INCREASED SIZE OF BOARD TO 12 MEMBERS - SEC FILING Source text: (https://bit.ly/2uWDtwR) Further company coverage:

BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx

* EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx

* EXELIXIS' PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA​

BRIEF-Exelixis Submits U.S. Supplemental NDA For Cabometyx

* EXELIXIS SUBMITS U.S. SUPPLEMENTAL NEW DRUG APPLICATION FOR CABOMETYX (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

Select another date: